Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Technology
Health & Fitness
Sports
About Us
Contact Us
Copyright
© 2024 PodJoint
Loading...
0:00 / 0:00
Podjoint Logo
US
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/e0/16/a7/e016a72a-3255-8e4c-804e-6855e685a274/mza_18057399343301114994.jpg/600x600bb.jpg
BioSpace
BioSpace
168 episodes
2 days ago
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Show more...
Life Sciences
Science
RSS
All content for BioSpace is the property of BioSpace and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Show more...
Life Sciences
Science
https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/39510587/39510587-1758146142040-b76a3d6fdffbc.jpg
What Do AI and Hammers Have in Common?
BioSpace
22 minutes 20 seconds
2 weeks ago
What Do AI and Hammers Have in Common?

In this episode, Lori Ellis and Colin Zick spend a little time further discussing some of the points brought up in the Bioprocessing Summit last month. AI is a tool, a powerful one but a tool. Understanding this, they explore the connections between hammers, AI, The Planet of the Apes and monoliths.

In the end, it is all about compliance.


Host

⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace


Guest

Colin Zick, Partner, Foley Hoag LLP


Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.